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Abstract
Background: Acknowledgment of all serious limitations to research evidence is important for patient care and scientific
progress. Formal research on how biomedical authors acknowledge limitations is scarce.
Objectives: To assess the extent to which limitations are acknowledged in biomedical publications explicitly, and implicitly
by investigating the use of phrases that express uncertainty, so-called hedges; to assess the association between industry
support and the extent of hedging.
Design: We analyzed reporting of limitations and use of hedges in 300 biomedical publications published in 30 high and
medium -ranked journals in 2007. Hedges were assessed using linguistic software that assigned weights between 1 and 5 to
each expression of uncertainty.
Results: Twenty-seven percent of publications (81/300) did not mention any limitations, while 73% acknowledged a median
of 3 (range 1–8) limitations. Five percent mentioned a limitation in the abstract. After controlling for confounders,
publications on industry-supported studies used significantly fewer hedges than publications not so supported (p = 0.028).
Limitations: Detection and classification of limitations was – to some extent – subjective. The weighting scheme used by
the hedging detection software has subjective elements.
Conclusions: Reporting of limitations in biomedical publications is probably very incomplete. Transparent reporting of
limitations may protect clinicians and guideline committees against overly confident beliefs and decisions and support
scientific progress through better design, conduct or analysis of new studies.
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Introduction
Peer review has been defined as a ‘‘negotiation between author
and journal about the scope of the knowledge claims that will
ultimately appear in print’’ [1]. Surely, the acknowledgement of a
study’s limitations should be part of those negotiations. Goodman
et al., in a study of the effect of peer review on manuscript quality,
found that the acknowledgment of limitations was the most
problematic item among 34 items of manuscript quality at
submission [2]. Ioannidis, assessing 400 papers from six high-
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ranked scientific journals, found that often no limitations appeared
to be mentioned [3]. Acknowledgement of limitations helps
readers understand the compromises that had to be made in a
study’s design, perhaps due to budget constraints or other factors.
Moreover, any discrepancies between the plans in the study
protocol and the realities of study execution, such as participant
non-adherence or incomplete data collection, may be highlighted.
These imperfections of study execution, in particular, may
otherwise be hard for readers to detect [4]. In 2002, Horton,
noticing ‘‘the chaotic nature of discussion sections’’ in a sample of
ten Lancet papers, wrote that the omission of limitations from the
discussion sections must be judged ‘‘a potential failure of journal
peer review’’ and he proposed a structured format for discussion
sections [5].
The recognition that scientific papers often try to convince or
influence readers [6], has led some scholars to study the linguistic
and rhetorical aspects of scientific writing [7]. Horton even
proposed ‘‘critical linguist analyses’’ as ‘‘a welcome third
component’’ of peer review in addition to medical subject matter
and statistical peer review [8].
Fletcher and Black discussing several ways in which ‘‘spin’’
occurs in the medical literature suggested that editors be more
vigilant with industry-sponsored studies [9], while Yank et al,
studying meta-analyses, found that for-profit funding was associ-
ated with more favorable conclusions, which were not accounted
for by the results [10].
In this contribution, we studied how limitations are presented in
biomedical research publications: explicitly, through an analysis of
limitations sections, and implicitly, through linguistic analysis of the
phrases used to moderate the strength of claims, also called
‘‘hedges’’ [11]. We hypothesized that industry-supported studies
use fewer hedges in order to strengthen claims [9,10,12].
Study objectives
In sub-study 1 we assessed (i) in what proportion of publications
limitations are acknowledged, (ii) what types of limitations are
discussed and (iii) in what manner, and (iv) whether the
uncertainty arising from acknowledged limitations is reflected in
the sections on implications for practice and conclusions. In sub-
study 2 we analyzed the amount of uncertainty that is expressed
and if that amount differed between journals, and industry-
sponsored and other research in particular.
Methods
Sub-study on the number and nature of acknowledged
limitations
From 10 general medical and 20 specialty journals, we included
the first 10 publications describing randomized controlled trials
(RCT), observational or diagnostic studies published in 2007.
Within the group of medical and specialty journals, half were top
journals (impact factor ranked 1st through 5th); the other half
ranked 11th through 15th, according to journal impact factors (ISI
2007). Using a structured assessment form (web appendix S1),
pairs of reviewers independently evaluated the proportion and
type of acknowledged limitations and whether the conclusions in
the abstract or discussion sections were tempered in light of
limitations. Any disagreements between reviewers were resolved
through discussion.
We assumed that 30% of publications would mention at least
one limitation and calculated that we needed 300 papers to
estimate that percentage with good precision (95% confidence
interval 65%). Results are reported using descriptive statistics.
Logistic regression analysis was used to explore whether general
medical and top ranking journals have different rates of
acknowledged limitations than specialty journals.
Sub-study to determine hedging scores
To determine hedging patterns, we used a software programme
[13]. This program determines a ‘‘hedging score’’ for each
sentence in a text. Hedges such as modal verbs (may, could), adverbs
(apparently, possibly), and lexical verbs (suggest [that], believe [that]) are
detected, and each hedge is given a score between one and five,
with higher scores reflecting more uncertainty [13]. The hedging
score of a sentence is the sum of its individual hedging scores. To
determine an article’s hedging score, we summed all hedging
scores for all sentences in the article. This score was then
normalized by dividing it by the number of words in the title,
abstract, introduction, methods, results, and discussion sections of
that publication. We deemed industry support present (coded yes
(1)/no (0)) if one of the following applied: full industry sponsorship
of the research; (at least one) authorship by industry employees;
industry donation of materials or lab space; industry payment for
statistician-consultants; industry payment for administrative costs;
industry payment for data collection; industry reviewing of a
manuscript prior to submission.
The variable that coded for study quality was assigned the label
‘good (1)’ if at least one criterion applied, and as ‘less than good (0)’
otherwise, where randomized trials had to have concealment of
randomization and/or proper random sequence generation, while
observational studies were assessed for adjustment of confounding
of the main association. Finally, the sample size was categorized in
6 categories using as cut-offs: 50; 100; 300; 1,000; 10,000. All data
were extracted by one reviewer and checked for errors by another
reviewer. Discrepancies were resolved through consensus. Three
hundred publications were potentially eligible to measure the
extent of hedging. We finally included 284 papers in the analyses
of hedges. The ten papers from the journal Clinical Gastroenterology
and Hepatology were missed in the transfer from our epidemiology
team (MP, GtR) to the linguistic team that assessed the hedges
(AG, PC) due to an administrative error that we detected only at
the analysis stage. For six papers, the software program used to
determine hedging patterns could not read the pdfs necessary to
determine the hedging score.
For the sub-study on the hedging scores, we did not perform a
sample size calculation, since we wanted to include as many of the
papers from sub-study 1 as possible. We performed four
multivariable linear regression analyses: two with the normalized
hedging score, and two with the number of author-acknowledged
limitations as the dependent variable, respectively [14,15]. A
dummy variable indicating industry support (coded as 1, 0
otherwise) was the independent variable of main interest. The
other variables (RCT (yes (1) vs no (0)), study quality (high (1) vs
non-high (0)), sample size (6 categories), p-value (3 categories) and
journal (28 dummy variables for the 29 journals)) served to control
for confounding. For the analyses on the numbers of limitations
acknowledged and the hedging scores in turn, we first used a
subset of 231 publications from which a meaningful p-value could
be extracted (excluding, for example, prevalence surveys and
diagnostic studies which report prevalence, and sensitivity and
specificity of a test, respectively, which are not always accompa-
nied by p-values). Next we analyzed 284 publications and
controlled for all measured confounders. In all analyses we added
variables to represent each of the 29 journals and controlled for
any journal effect. The New England Journal of Medicine (NEJM)
served as the reference category [14,15]. In two sensitivity
analyses, we assessed the stability of our results using the Huber-
White sandwich estimator instead of the 28 dummies or used a
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random intercept model to account for the intra-journal clustering
of papers which was caused by our method of sampling [16]. We
visually checked the normality assumption using standardized
normal probability plots. Stata 10.1 (College Station, TX, USA)
software was used for all statistical analyses.
Results
Sub-study on the numbers and nature of acknowledged
limitations
Eighty-one of the 300 publications did not acknowledge any
limitation (27%, 95%CI from 22 to 32%). Two hundred nineteen
publications acknowledged a median of 3 (range 1–8) limitations in
the discussion section (73%, 68 to 78%), whereas 16 acknowledged
a limitation in the abstract (5.3%, 3.3 to 8.5%). 186/300 (62%, 56
to 67%) of acknowledged limitations referred to aspects of internal
validity, mostly to measurement errors (n = 149). 114/300 (38%,
33 to 44%) of acknowledged limitations referred to aspects of
external validity, mostly to selected study populations (n = 115).
183/219 of the publications did not temper the conclusions
because of limitations (84%, 78 to 88%). Publications in general
medical journals were more likely to acknowledge limitations than
publications in specialty journals (odds ratio 2.27, 95% CI from
1.27 to 4.10), particularly in abstracts (3.57, 1.27 to 10.0).
Conclusions were not tempered more frequently in general
medical journals. (0.98, 0.43 to 2.33). Journals’ tier (rank 1–5 vs
rank 11–15) did not affect these estimates.
Sub-study on determinants of the hedging scores and
numbers of acknowledged limitations
There were 61 (21.5%) industry-supported publications by our
criteria. Table 1 shows that, on average, industry-supported
publications were RCTs more often, were published in journals
with higher impact factors, and had lower p-values. The
proportion of good quality publications was similar in research
with and without industry support. The interquartile range for the
non-normalized weighted hedging score was from 86 to 160. If we
assume an average hedging weight of three (the range was 1 to 5),
this means that there were between 29 (86/3) and 54 (160/3)
hedges with a weight of three in a publication with a length of
about 3,255 (25th centile) to 4,471 (75th centile) words. Tables 2
and 3 show the results from the regression analyses. Hedging
scores were lower (2.66 per 100 words) for industry-supported
publications than for other publications (3.54), with a mean
difference of 0.88 (95% CI 0.55 to 1.22). After controlling for
confounding through multivariable linear regression analysis, this
difference changed to 0.53 (0.06 to 1.00) for the set of 231
publications in which also a meaningful p-value could be
extracted. The difference was 0.61 (0.15 to 1.07) for the full set
of 284 publications, not controlling for the magnitude of the p-
value.
Table 3 shows that, on average, industry-supported publications
acknowledged 0.65 (0.25 to 1.30) fewer limitations than publica-
tions not supported by industry after full control for confounding.
Papers published in the British Journal of Psychiatry, the British
Medical Journal and the Annals of Family Medicine used around
1.5 to 2 more hedges per 100 words than the NEJM. The
publications from the Annals of Surgical Oncology acknowledged
2.18 fewer, Medicine 2.61 fewer, those from the American Journal
of Medicine 1.58 more, Annals of Internal Medicine 1.73, and
Chest 2.90 more limitations than those from the NEJM.
The results from the two sensitivity analyses were slightly less
conservative than the results from the primary analyses presented
here (data available on request).
Discussion
We found that over a quarter of biomedical publications do not
discuss any limitations. In abstracts, limitations are rarely
mentioned. Industry-supported publications appear to express less
uncertainty after controlling for factors that justify confidence in
the study results. Finally, we found major differences between
journals in how uncertainty is expressed and limitations acknowl-
edged.
Complete reporting of study design, success of execution and, if
appropriate, statistical analysis give meaning to the results of
empirical studies. That is why, in science, we value (detailed)
methods sections in research publications [4]. In addition,
methods sections facilitate attempts at replication by others. It is
often easier to plan a flawless study than to execute one. This
distinction is important since readers can increasingly read the
investigators’ intentions through, for example, trial registration
websites or separate publications dealing solely with a study’s
rationale, design and protocol details [17]. Access to details on
study execution or log books is still rare [18]. In principle, one
could place an unabridged list of all important differences between
the study plan and actual execution in an appendix to a
manuscript. However, deciding which events during a study’s
execution count as protocol violations and which violations cause
limitations requires judgment [3]. Consider two examples: If the
actual time interval between blood sampling and refrigerating the
samples was 2 percent longer than stated in the protocol in 29 out
of 1,000 samples collected for later determination of some
compound, should one report that? By contrast, if in a randomized
trial, a post-hoc chemical analysis shows that the interventional
drug contained only 10% of the intended amount of the active
compound, should that be acknowledged as a study limitation
[19]? Our findings indicate that many authors appear not to be
aware of limitations or are reluctant to admit them even after peer
review.
Obviously, the present work would be quite incomplete if we did
not address its limitations. First, for sub-study 1, the body of papers
we assessed is five years old. However, we think that is unlikely
that the awareness about acknowledging limitations has changed
much, if at all, in recent years. Second, in sub-study 2, we lost 10,
and could not analyze six of our 300 publication sample due to
administrative errors or technical problems. Third, the software
application used to calculate the hedging scores was not perfect. In
particular, its accuracy is only about 93% [13]. Fourth, the weights
assigned to the types of hedges are somewhat arbitrary. Fifth, it
would have been interesting to determine an article’s hedging
score separately for each of the most relevant sections such as the
title, abstract, results and discussion sections and thus be able to
fine-tune the normalization using the word count, which was now
summed across the whole publication. Sixth, the binary coding of
industry support will have caused some misclassification. If
misclassification were random, we may have underestimated the
lower degree of hedging in industry-supported publications. A
finer scale of industry support would have been attractive, but
difficult to achieve.
As far as we are aware, research on the use of limitations is
scarce. Previously, Ioannidis reported that 17% of publications
mentioned any limitations. However, he used an automated search
strategy on the texts that is likely to have missed acknowledgments
of limitations [3]. Goodman et al., in a masked before-after study
on manuscripts submitted to the Annals of Internal Medicine,
found that newly submitted manuscripts scored worst on reporting
about blinding, non-inclusions, drop-outs, multivariate methods,
generalization of results and study limitations. Of those, reporting
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on limitations and generalization benefited most from peer review
by physicians and epidemiologists trained in research methods,
although even after peer review, the section on limitations
remained among the weaker sections [2]. Our work does not
shed light on the question of why industry support should lead to
the expression of less uncertainty, all other factors being equal?
However, there is a vast field specialized in writing texts for the
industry and Carl Elliott wrote on the more cynical aspects thereof
[20]. More recently, Medtronic, a US medical device company,
has been accused of manipulating 13 journal articles and paying
large amounts of money to authors [21].
Although the STROBE statement encourages authors to
‘‘Discuss limitations [..], taking into account sources of potential
bias or imprecision. Discuss both direction and magnitude of any
potential bias’’, ‘‘Give a cautious overall interpretation of results
considering objectives, limitations, [..] etc.’’ and the CONSORT
statement urges authors to address ‘‘Trial limitations, addressing
sources of potential bias, imprecision, and, if relevant, multiplicity
of analyses.’’ [22,23], it will probably not be easy to curb the
tendency of many authors to only sparingly admit issues that were
imperfect by design, execution or both. Until a major change in
attitudes occurs, ways to improve the reporting of all serious
Table 1. Descriptives of 284 publications from medium and top tier biomedical journals used to count and classify limitations and
calculate the hedging scores.
No industry support Industry support Total
Characteristic
RCT, n (%) 33 (14.8) 47 (77.1) 80 (28.2)
Sample size 366 (100;1986) 313 (182;1520) 356 (103;1891)
Impact factor 5.78 (4.36;10.68) 10.68 (6.42;16.23) 6.36 (4.47;12.58)
p-value (n = 231) .020 (.001;.050) .011 (.001;.050) .018 (.001;.050)
Quality good, n (%) 121 (54.3) 35 (57.4) 156 (54.9)
Top tier journal, n (%) 108 (48.4) 46 (75.4) 154 (54.2)
Raw score 124 (89;165) 101 (83;137) 116.5 (86;160)
No. words 3699 (3155;4341) 4195 (3608;5114) 3752 (3255;4471)
No. lines 168 (146;203) 204 (169;262) 175 (149;212)
Hedging score (%) 3.4 (2.6;4.3) 2.4 (1.8;3.2) 3.2 (2.4;4.2)
No. acknowledged limitations 0 (2;4) 0 (1;3) 0 (2;3.5)
Total, n (%) 223 (78.5) 61 (21.5) 284 (100)
Numbers are medians and (in brackets) interquartile ranges unless indicated otherwise; RCT = randomized controlled trial; Raw scores indicate the number of hedges in
a publication (weighted by a hedging weight between 1 and 5); the hedging score is calculated by dividing the raw score by the number of words in (the relevant
sections of) the publication. A hedging score of 3.0% indicates that on every 100 words there is one expression of uncertainty with a weight of 3 (or three with a
hedging weight of 1, or less than 1, but with a hedging weight higher than 3, that is, expressing more uncertainty).
doi:10.1371/journal.pone.0073623.t001
Table 2. Results of regression analyses for the hedging scores per 100 words.
Hedging score per 100 words
No industry support Industry support Difference
Unadjusted (n = 284) 3.54 (3.37–3.71) 2.66 (2.37–2.94) 0.88 (0.55–1.22)
Fully adjusted (n = 231) 0.53 (0.06–1.00)
-Journals
British Journal of Psychiatry 1.91 (0.43–3.40){
British Medical Journal 1.46 (0.32–2.61){
Annals of Family Medicine 1.92 (0.84–2.99){
Not adjusted for P-value (n = 284) 0.61 (0.15–1.07)
-Journals
Heart 1.31 (0.14–2.47){
Pediatrics 1.22 (0.07–2.24){
British Medical Journal 1.58 (0.44–2.71){
Annals of Family Medicine 1.96 (0.88–3.04){
{Journal differed significantly from New England Journal of Medicine (reference category).
Full adjustment was for Randomized Controlled Trial (yes/no), quality (high/non-high), sample size (6 categories), journal (28 dummies), magnitude of the P-value (3
categories).
doi:10.1371/journal.pone.0073623.t002
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limitations in biomedical research reports may require a structured
approach at the editorial offices: Explicit journals’ instructions for
authors, more structured support and dedicated checklists for peer
reviewers, more structured approaches at the editorial offices,
perhaps involving automatic comparison of a manuscript’s
hedging score to reference values for hedging scores conditional
on the study’s design and outcome. Finally, checks on the number
and nature of limitations acknowledged and if acknowledged
limitations are reflected in the strength of the conclusions drawn
may be useful. After publication, web-based rapid response
facilities and acknowledgment for those critics who enlighten
readers as to serious limitations may be considered. On the other
hand, the authors may sometimes be the only ones who know
about a limitation due to problems during study execution and
have to decide whether it is important enough to be mentioned as
a limitation. We believe that in general, editors may encourage
authors to write about their methods used more extensively at the
expense of the length of the discussion sections that are sometimes
filled with much speculation. Spending at least a fixed proportion
of the discussion section on limitations may also be explored [5].
We would also welcome if more journals followed the Annals of
Internal Medicine’s rule that the abstract should mention at least
one limitation. In the meantime perhaps the National Library of
Medicine may consider adding limitations to the abstracts in
PubMed.
Replication of this work is needed. Our work may be improved
by calculating hedging scores per section. Sensitivity analyses with
the hedging-weights may shed light on the role of the weights
assignment in the hedging software. Some of the ideas we
suggested above may be carried out as research projects at the
editorial offices. For example, we may try to assess if more
structured approaches are implementable, what the challenges
involved are with such approaches, and what effects can be
measured after implementation on for example transparent
reporting, time investment needed, authors avoiding journals with
a strict approach in place, and effects on journals’ impact factors.
Long-term effects may involve the quality of clinical practice
guidelines and patient care and its outcomes. And finally, larger
studies may try to replicate and investigate in depth how by-
journal hedging score variation is related to editorial policies.
In conclusion, our data show that reporting of limitations to
original biomedical research is probably incomplete. Either
directly, through clinical decision-making by evidence-based
clinicians or indirectly through its effects on systematic reviews
and clinical guidelines, optimal patient care may be jeopardized.
Finally, scientific progress may be slowed down: reporting
limitations more completely would aid the design and implemen-
tation of future studies. An appropriate amount of hedging given
these limitations could further guide future scientific inquiry.
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